Innate Pharma (IPH) Q2 2025 earnings summary

Executive summary

• Strategic focus on advancing IPH4502, Lacutamab, and Monalizumab, with organizational streamlining and a planned 30% reduction in staffing to prioritize resources.

• €15m equity investment by Sanofi in April 2025, strengthening the partnership, capital base, and resulting in a 9.05% stake.

• Corporate governance changes include a shift to a CEO/board structure, new board appointments, and establishment of an R&D Committee.

• Chief Scientific Officer Eric Vivier transitioned to an advisory role, with Yannis Morel assuming CSO responsibilities.

• Emphasis on leveraging differentiated antibody engineering and clinical data to advance transformative cancer therapies, focusing on high unmet needs in oncology.

Financial highlights

• H1 2025 revenue and other income totaled €4.9m, mainly from collaborations with AstraZeneca and Sanofi, and government research funding.

• Operating expenses decreased to €30.3m, with R&D expenses at €20.5m (67.8% of total), down 29% year-over-year.

• Cash, cash equivalents, and financial assets totaled €70.4m as of June 30, 2025, down from €91.1m at year-end 2024, providing runway through Q3 2026.

• Net loss for H1 2025 was €21.3m, compared to a net loss of €24.8m in H1 2024.

• Net financial gain of €4.1m in H1 2025, mainly from favorable foreign exchange impacts.

Outlook and guidance

• Cash runway, including restructuring impact, extends to end of Q3 2026.

• IPH4502 Phase 1 enrollment expected to complete by end of Q1 2026, with preliminary safety and activity data in H1 2026.

• Lacutamab Phase 3 protocol near completion; trial initiation targeted for 2026 pending financing or partnership, with potential accelerated approval in 2027.

• Monalizumab Phase 3 PACIFIC-9 trial fully recruited; primary completion expected H1 2026, data in H2 2026.

• Streamlining and organizational changes to be completed in H1 2026.